Stock CMPS COMPASS PATHWAYS PLC
Add to a list
To use this feature you must be a member
Log inSign up

All News COMPASS Pathways plc

Equities

CMPS

US20451W1018

Real-time Estimate Cboe BZX
Other stock markets
 01:25:36 2024-05-20 pm EDT 		5-day change 1st Jan Change
7.93 USD +1.15% Intraday chart for COMPASS Pathways plc -2.22% -9.26%
May. 09 Transcript : COMPASS Pathways plc - Shareholder/Analyst Call
May. 08 Transcript : COMPASS Pathways plc, Q1 2024 Earnings Call, May 08, 2024

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
COMPASS Pathways : 2024 AGM Voting Results
PU
Transcript : COMPASS Pathways plc - Shareholder/Analyst Call
Transcript : COMPASS Pathways plc, Q1 2024 Earnings Call, May 08, 2024
COMPASS Pathways plc Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights
GL
Compass Pathways plc Reports Top-Line Results from an Open-Label Phase 2 Study Evaluating the Safety and Tolerability of Investigational COMP360 Psilocybin Treatment in 22 Patients with Post-Tail Stress Disorder
CI
Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder
GL
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
GL
Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression
GL
Compass Pathways and Journey Clinical Establish Research Collaboration Agreement to Inform the Training of Healthcare Providers and Delivery Model for Comp360 Psilocybin Treatment, If Approved for Treatment-Resistant Depression
CI
Compass Pathways Insider Sold Shares Worth $597,964, According to a Recent SEC Filing
MT
Compass Pathways Insider Sold Shares Worth $597,964, According to a Recent SEC Filing
MT
Clarify Pharma to change name to File Forge Technology
AN
Compass Pathways Insider Sold Shares Worth $461,332, According to a Recent SEC Filing
MT
Compass Pathways Insider Sold Shares Worth $461,332, According to a Recent SEC Filing
MT
Compass Pathways Insider Sold Shares Worth $445,552, According to a Recent SEC Filing
MT
Compass Pathways Insider Sold Shares Worth $445,552, According to a Recent SEC Filing
MT
Morgan Stanley Initiates COMPASS Pathways at Overweight With $30 Price Target
MT
ADRs End Lower; NuCana Slides 15%
DJ
Compass Pathways Co-Founders Step Down From Board; David Norton Named Interim Chair; Shares Fall
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CMPS Stock
  4. News COMPASS Pathways plc
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW